Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Detrol LA Clear all
Terminated Phase 3 Interventional Results available

A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain

NCT05658874
View directory record Official record
Conditions
Interstitial Cystitis, Levator Spasm, Bladder Pain Syndrome
Interventions
Multimodal Bundle Drugs, Operative Cystoscopy, Behavioral health consultation/therapy, Pelvic floor physical therapy, Usual Urogynecologic care, Bladder Instillation, Vaginal estrogen, Methenamine, Amitriptyline/Gabapentin
Drug · Procedure · Behavioral + 1 more
Lead sponsor
Jocelyn Fitzgerald
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 10, 2026, 4:11 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.

NCT00323635
View directory record Official record
Conditions
Urinary Incontinence
Interventions
tolterodine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 10, 2026, 4:11 PM EDT
Completed Phase 4 Interventional

Detrol LA In Men With Overactive Bladder.

NCT00282932
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
Detrol LA
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
40 Years and older · Male only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
11
States / cities
Anaheim, California • La Mesa, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 10, 2026, 4:11 PM EDT
Completed No phase listed Observational

A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)

NCT02386072
View directory record Official record
Conditions
Urinary Bladder Overactive, Overactive Bladder, Urinary Bladder Diseases, Urologic Diseases
Interventions
mirabegron, antimuscarinic medication
Drug
Lead sponsor
Astellas Scientific & Medical Affairs, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
75
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 10, 2026, 4:11 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction

NCT01741454
View directory record Official record
Conditions
Ureteral Obstruction
Interventions
Tamsulosin, Tolterodine ER
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Sep 10, 2026, 4:11 PM EDT
Completed Phase 4 Interventional

Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.

NCT00230789
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Tolterodine ER 4 mg QD, OAB Patient Behavioral Training Material
Drug · Behavioral
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
51
States / cities
Phoenix, Arizona • Sun Lakes, Arizona • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 10, 2026, 4:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Brain-Centered Therapy Versus Medication for Urgency Urinary Incontinence : Hypnotherapy Or Pharmacotherapy

NCT01829425
View directory record Official record
Conditions
Urinary Incontinence, Urge
Interventions
Anticholinergic medications, Hypnotherapy
Drug · Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 10, 2026, 4:11 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Combined Behavioral and Drug Treatment of Overactive Bladder in Men

NCT01175382
View directory record Official record
Conditions
Overactive Bladder, Lower Urinary Tract Symptoms
Interventions
Behavioral training, Tolterodine + tamsulosin, Combined Behavioral + Drug Therapy
Behavioral · Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years and older · Male only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Birmingham, Alabama • Atlanta, Georgia • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Sep 10, 2026, 4:11 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effects Of Detrol LA On Memory And Cognition In Elderly Population

NCT00411437
View directory record Official record
Conditions
Memory, Cognition
Interventions
Tolterodine ER, Oxybutynin ER
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
65 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
9
States / cities
Tucson, Arizona • Brooksville, Florida • DeLand, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 10, 2026, 4:11 PM EDT
Completed Phase 4 Interventional Results available

Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics

NCT04090190
View directory record Official record
Conditions
Urinary Incontinence, Urgency Urinary
Interventions
Oxybutynin, Solifenacin, Tolterodine, Trospium, or Fesoterodine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Sep 10, 2026, 4:11 PM EDT
Completed Phase 3 Interventional

Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder

NCT00454740
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
solifenacin succinate
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
104
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Sep 10, 2026, 4:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects

NCT00703703
View directory record Official record
Conditions
Healthy
Interventions
Darifenacin, Tolterodine, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
21
States / cities
Phoenix, Arizona • Tempe, Arizona • Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Sep 10, 2026, 4:11 PM EDT
Completed Phase 4 Interventional

Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women

NCT00143481
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Tolterodine ER 4mg QD
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
58
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 10, 2026, 4:11 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)

NCT02138747
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
Mirabegron, Tolterodine ER
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
22
States / cities
Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Sep 10, 2026, 4:11 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily

NCT01089751
View directory record Official record
Conditions
Overactive Bladder
Interventions
trospium chloride, placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
La Mesa, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2013 · Synced Sep 10, 2026, 4:11 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treatment of Incontinence Without Memory Problems

NCT02436889
View directory record Official record
Conditions
Urge Incontinence, Urinary Incontinence, Urge
Interventions
Mirabegron, Tolterodine Tartrate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 10, 2026, 4:11 PM EDT
Completed Phase 4 Interventional Results available

Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)

NCT00939120
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Tolterodine ER 4mg, Placebo, Pre-randomization Dutasteride
Drug
Lead sponsor
Siami, Paul F., M.D.
Other
Eligibility
50 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Newburgh, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Sep 10, 2026, 4:11 PM EDT
Completed Phase 4 Interventional

Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction

NCT00147654
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Tolterodine ER 4 mg QD, Tamsulosin 0.4 mg QD
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
40 Years and older · Male only
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
95
States / cities
Birmingham, Alabama • Homewood, Alabama • Tucson, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 10, 2026, 4:11 PM EDT